Literature DB >> 19395873

Post-transcriptional regulation in lymphocytes: the case of CD154.

Stefano Vavassori1, Lori R Covey.   

Abstract

The control of mRNA decay is emerging as an important control point and a major contributor to gene expression in both immune and non-immune cells. The identification of protein factors and cis-acting elements responsible for transcript degradation has illuminated a comprehensive picture of precisely orchestrated events required to both regulate and establish the decay process. One gene that is highly regulated at the post-transcriptional level is CD40 ligand (CD154 or CD40L). CD154 on CD4(+) T cells is tightly controlled by an interacting network of transcriptional and post-transcriptional processes that result in precise surface levels of protein throughout an extended time course of antigen stimulation. The activation-induced stabilization of the CD154 transcript by a polypyrimidine tract-binding protein (PTB)-complex is a key event that corresponds to the temporal expression of CD154. In this review, we discuss known and potential roles of major mRNA decay pathways in lymphocytes and focus on the unique post-transcriptional mechanisms leading to CD154 expression by activated CD4(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19395873      PMCID: PMC2880545          DOI: 10.4161/rna.6.3.8581

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  109 in total

1.  Nitric oxide post-transcriptionally up-regulates LPS-induced IL-8 expression through p38 MAPK activation.

Authors:  Penglin Ma; Xiaolin Cui; Shuibang Wang; Jianhua Zhang; Ervant V Nishanian; Weihan Wang; Robert A Wesley; Robert L Danner
Journal:  J Leukoc Biol       Date:  2004-06-03       Impact factor: 4.962

Review 2.  New perspectives on connecting messenger RNA 3' end formation to transcription.

Authors:  Nick Proudfoot
Journal:  Curr Opin Cell Biol       Date:  2004-06       Impact factor: 8.382

3.  CD28 ligation in T-cell activation: evidence for two signal transduction pathways.

Authors:  J A Ledbetter; J B Imboden; G L Schieven; L S Grosmaire; P S Rabinovitch; T Lindsten; C B Thompson; C H June
Journal:  Blood       Date:  1990-04-01       Impact factor: 22.113

4.  Nucleolin is a second component of the CD154 mRNA stability complex that regulates mRNA turnover in activated T cells.

Authors:  Karnail Singh; Jennifer Laughlin; Penelope A Kosinski; Lori R Covey
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

5.  Protein kinase A phosphorylation modulates transport of the polypyrimidine tract-binding protein.

Authors:  Jiuyong Xie; Ji-Ann Lee; Tracy L Kress; Kimberly L Mowry; Douglas L Black
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-08       Impact factor: 11.205

6.  A multi-protein complex containing cold shock domain (Y-box) and polypyrimidine tract binding proteins forms on the vascular endothelial growth factor mRNA. Potential role in mRNA stabilization.

Authors:  Leeanne S Coles; M Antonetta Bartley; Andrew Bert; Julie Hunter; Steven Polyak; Peter Diamond; Mathew A Vadas; Gregory J Goodall
Journal:  Eur J Biochem       Date:  2004-02

7.  Molecular and biological characterization of a murine ligand for CD40.

Authors:  R J Armitage; W C Fanslow; L Strockbine; T A Sato; K N Clifford; B M Macduff; D M Anderson; S D Gimpel; T Davis-Smith; C R Maliszewski
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

8.  The dinucleotide repeat polymorphism in the 3'UTR of the CD154 gene has a functional role on protein expression and is associated with systemic lupus erythematosus.

Authors:  M J Citores; I Rua-Figueroa; C Rodriguez-Gallego; A Durántez; M I García-Laorden; C Rodríguez-Lozano; J C Rodríguez-Pérez; J A Vargas; P Pérez-Aciego
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

9.  A novel heterogeneous nuclear RNP protein with a unique distribution on nascent transcripts.

Authors:  S Piñol-Roma; M S Swanson; J G Gall; G Dreyfuss
Journal:  J Cell Biol       Date:  1989-12       Impact factor: 10.539

10.  A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery.

Authors:  Roberto Gherzi; Kyung-Yeol Lee; Paola Briata; Daniel Wegmüller; Christoph Moroni; Michael Karin; Ching-Yi Chen
Journal:  Mol Cell       Date:  2004-06-04       Impact factor: 17.970

View more
  19 in total

Review 1.  Post-transcriptional regulons coordinate the initiation and resolution of inflammation.

Authors:  Paul Anderson
Journal:  Nat Rev Immunol       Date:  2010-01       Impact factor: 53.106

2.  Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome.

Authors:  Caroline Y Kuo; Joseph D Long; Beatriz Campo-Fernandez; Satiro de Oliveira; Aaron R Cooper; Zulema Romero; Megan D Hoban; Alok V Joglekar; Georgia R Lill; Michael L Kaufman; Sorel Fitz-Gibbon; Xiaoyan Wang; Roger P Hollis; Donald B Kohn
Journal:  Cell Rep       Date:  2018-05-29       Impact factor: 9.423

Review 3.  Post-transcriptional coordination of immunological responses by RNA-binding proteins.

Authors:  Panagiota Kafasla; Antonis Skliris; Dimitris L Kontoyiannis
Journal:  Nat Immunol       Date:  2014-06       Impact factor: 25.606

4.  Coordinate regulation of GATA-3 and Th2 cytokine gene expression by the RNA-binding protein HuR.

Authors:  Cristiana Stellato; Matthew M Gubin; Joseph D Magee; Xi Fang; Jinshui Fan; Danielle M Tartar; Jing Chen; Garrett M Dahm; Robert Calaluce; Francesca Mori; Glenn A Jackson; Vincenzo Casolaro; Craig L Franklin; Ulus Atasoy
Journal:  J Immunol       Date:  2011-05-25       Impact factor: 5.422

5.  The human glucocorticoid receptor as an RNA-binding protein: global analysis of glucocorticoid receptor-associated transcripts and identification of a target RNA motif.

Authors:  Faoud T Ishmael; Xi Fang; Kenneth R Houser; Kenneth Pearce; Kotb Abdelmohsen; Ming Zhan; Myriam Gorospe; Cristiana Stellato
Journal:  J Immunol       Date:  2010-12-10       Impact factor: 5.422

6.  Polypyrimidine tract-binding protein is critical for the turnover and subcellular distribution of CD40 ligand mRNA in CD4+ T cells.

Authors:  Rodrigo Matus-Nicodemos; Stefano Vavassori; Moraima Castro-Faix; Anibal Valentin-Acevedo; Karnail Singh; Valentina Marcelli; Lori R Covey
Journal:  J Immunol       Date:  2011-01-17       Impact factor: 5.422

7.  Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Authors:  Rosa Lapalombella; Leslie Andritsos; Qing Liu; Sarah E May; Rebekah Browning; Lan V Pham; Kristie A Blum; William Blum; Asha Ramanunni; Chelsey A Raymond; Lisa L Smith; Amy Lehman; Xiaokui Mo; David Jarjoura; Ching-Shih Chen; Richard Ford; Christoph Rader; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

8.  Conditional knockout of the RNA-binding protein HuR in CD4⁺ T cells reveals a gene dosage effect on cytokine production.

Authors:  Matthew M Gubin; Patsharaporn Techasintana; Joseph D Magee; Garrett M Dahm; Robert Calaluce; Jennifer L Martindale; Maryln S Whitney; Craig L Franklin; Cindy Besch-Williford; John W Hollingsworth; Kotb Abdelmohsen; Myriam Gorospe; Ulus Atasoy
Journal:  Mol Med       Date:  2014-03-20       Impact factor: 6.354

9.  Posttranscriptional gene regulation of IL-17 by the RNA-binding protein HuR is required for initiation of experimental autoimmune encephalomyelitis.

Authors:  Jing Chen; Jason Cascio; Joseph D Magee; Patsharaporn Techasintana; Matthew M Gubin; Garrett M Dahm; Robert Calaluce; Shiguang Yu; Ulus Atasoy
Journal:  J Immunol       Date:  2013-10-28       Impact factor: 5.422

10.  Differential modulation by delta9-tetrahydrocannabinol (∆9)-THC) of CD40 ligand (CD40L) expression in activated mouse splenic CD4+ T cells.

Authors:  Thitirat Ngaotepprutaram; Barbara L F Kaplan; Robert B Crawford; Norbert E Kaminski
Journal:  J Neuroimmune Pharmacol       Date:  2012-08-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.